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Background : Myocardial blush grade (MBG) is an angiographic parameter to describe the adequacy of myocardi-
al reperfusion. The correlation between myocardial blush and the clinical outcome following chronic total 
occlusion (CTO) recanalization is still unclear. Our study aimed to investigate the impact of myocardial blush 
after CTO recanalization on the clinical outcome of CCS patients.
Design : A retrospective cohort study was conducted. Patients who underwent CTO recanalization were divided 
into two groups based on the myocardial blush. Patients were classified as having good myocardial blush (MBG 
category 2 to 3 or QUBE 0 to 10.2) and poor myocardial blush (MBG category 0 to 1 or QUBE 10.2 to 36.4). The 
outcome measured was the improvement of angina measured using the Seattle Angina Questionnaire (SAQ) and 
the reduction of antianginal drug regimens.
Results : The follow-up period was ranging from 2 to 24 months following the CTO recanalization procedure. The 
SAQ for physical limitation (83.86 ± 16.11 vs. 77.92 ± 3.44; p = 0.247), angina frequency (85.27 ± 17.44 vs. 
74.76 ± 22.05; p = 0.105), and quality of life (73.24 ± 3.41 vs. 72.82 ± 3.56; p = 0.932) between the two 
groups was not significantly different. Good myocardial blush was not correlated with the reduction of antiangi-
nal drug regimens (10 (52.6) vs. 8 (40); p = 0.639).
Conclusion : Myocardial blush post-CTO recanalization was not associated with the improvement of angina 
symptoms and the reduction of antianginal drug regimens among patients with CCS. 
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Chronic total occlusion; Myocardial blush; 
Chronic coronary syndrome; Angina
 CTO  in coronary arteries was identified in about 15% to 
30% of patients who underwent invasive diagnostic coronary angiogra-
phy.1 Until now, the revascularization strategy of CTO remains the 
main problem and is a common cause for a patient's referral for 
coronary artery bypass graft (CABG) surgery.2 Some studies revealed 
that CTO recanalization could provide some advantages, including 
improving left ventricular systolic function, symptoms, and quality of 
life. Moreover, better tolerance of subsequent ischemic events, possibly 
improved long-term survival, arrhythmia burden reduction, and 
long-term health care costs reduction also could be achieved by CTO 
recanalization.3,4 The revascularization strategy in multivessel disease 
with concomitant CTO may be challenging. The existence of CTO 
remains the largest and most significant technical challenge to achieve 
complete revascularization by percutaneous coronary intervention
(PCI) approach.5
 The primary goal of revascularization is not only to return 
the epicardial coronary artery blood flow but also to ensure and 
maintain adequate myocardial perfusion.6 A simple clinical equipment 
described the myocardial reperfusion effectiveness is lacking.  So far, 
noninvasive approaches have not been applicable in daily clinical 
practice and the abroad used angiographic parameter, Thrombolysis In 
Myocardial Infarction (TIMI) flow grade, depicts the epicardial blood 
flow instead of myocardial.7 MBG is an angiographic parameter to 
describe the adequacy of myocardial reperfusion. An open-source 
software program named The Quantitative Blush Evaluator (QuBE) 
provides a feasible, practical, and reproducible method to measure 
myocardial perfusion.8 The correlation between myocardial blush and 
the clinical outcome following CTO recanalization is still unclear. Our 
study aimed to investigate the impact of myocardial blush after CTO 
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recanalization on the clinical outcome of CCS patients.
2. Method
2.1. Study Design
 We conducted a retrospective cohort study in the catheter-
ization laboratory of Saiful Anwar General Hospital Malang from 
August to November 2016. The study protocol conformed to the 1975 
Declaration of Helsinki's ethical guidelines. The study protocol was 
recognized and approved by the ethical committee of Saiful Anwar 
General Hospital.
2.2. Patient Selection
 Patients who underwent PCI between January 2014 and 
August 2016 were identified retrospectively from our database. The 
inclusion criteria included: (1) CCS patient receiving optimal medical 
treatment; (2) CCS patient who had CTO in at least one coronary artery 
in an angiographic examination; and (3) CCS patient aged at least 40 
years. The exclusion criteria included: (1) Patient with non-cardiac 
comorbid with a life expectancy of <1 year; (2) Patients with the 
barrier to underwent a medical examination and study follow-up at the 
cardiology outpatient clinic of Saiful Anwar General Hospital; (3) 
Patients with severe physical limitations that were not allowed to do 
daily physical activities; and (4) Patients with routine medications from 
the psychiatrist. Data on their current health conditions were obtained 
either from the phone call or from their last office visit in November 
2016. 
2.3. Procedural Aspect
 Before the procedure, all patients were treated with a 
loading dose of aspirin and clopidogrel. CTO recanalization procedures 
were mainly conducted through the femoral artery access and 
antegrade approach with 7 Fr guiding catheters. For each patient, the 
CTO recanalization procedure was performed under the GE Healthcare 
Innova 2100 Cardiovascular Imaging system. The angiographic 
sequence was recorded using standardized projections until the visual 
confirmation of the myocardial washout phase. At the beginning of the 
procedure, patients received a single bolus of unfractionated heparin. 
Procedural success is defined as the successful CTO recanalization and 
dilation of ≥ 1 CTO/patient with or without stent implantation, residu-
al stenosis of < 50%, and TIMI flow grade > 1 without major adverse 
cardiovascular events (MACE).9,10 
2.4. Exposure and Outcomes
 CTO is defined as the total (100%) occlusion of the coronary 
artery with TIMI 0 flow for at least three months.11 Patients who under-
went CTO recanalization were divided into two groups based on the 
myocardial blush. Patients were classified as having good myocardial 
blush if they had the MBG category 2 to 3 (QUBE 0 to 10.2). However, 
patients were classified as having poor myocardial blush if they had the 
MBG category 0 to 1 (QUBE 10.2 to 36.4). The QuBE program needs an 
angiogram recorded immediately after PCI only. Moreover, quantita-
tive blush assessment limits intra- and inter-observer variability, a 
typical phenomenon in visually assessed myocardial blush grading.8,12 
Following PCI, all patients got dual antiplatelet treatment, including 
aspirin and clopidogrel. The outcome measured was the improvement 
of angina measured using the Seattle Angina Questionnaire (SAQ), 
which has been extensively studied and validated in cardiac patients.4,13 
The outcome measured also included the reduction of antianginal drug 
regimens, including isosorbide dinitrate or nitroglycerine. The 
follow-up duration was ranging from 2 to 24 months.
2.5. Statistical analysis
 All data obtained were analyzed using IBM SPSS 24 
software. Numerical data were presented as mean and standard 
deviation, while categorical data were presented as number and 
percentage. Data normality assessment was conducted using the 
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Variable Good myocardial blush (MBG 2-3) 
(n = 19) 
Poor myocardial blush (MBG 0-1) 
(n = 21) 
Total 
(n = 40) 
p-Value 
Age, year 54.8 ± 10 58.3 ± 7.2 57 ± 8 0.211 
Sex, male 19 (100) 17 (81) 36 (90) 0.108 
BMI, kg/m2 24.2 ± 4.1 25.1 ± 3.2 24 ± 3 0.405 
Hypertension 10 (52.6) 11 (52.4) 21 (52.5) 1.000 
Diabetes 5 (26.3) 11 (52.4) 16 (40) 0.175 
Dyslipidemia 4 (21.1) 4 (20) 8 (20) 1.000 
Cigarette smoking 10 (52.6) 12 (57.1) 22 (55) 1.000 
Family history of CAD 3 (15.8) 5 (23.8) 8 (20) 0.698 
History of ACS 8 (42.1) 10 (47.6) 18 (45) 0.975 
Heart failure 7 (36.8) 10 (47.6) 17 (42.5) 0.713 
Stroke 1 (5.3) 3 (14.3) 4 (10) 0.607 
CKD 6 (31.6) 11 (52.4) 17 (42.5) 0.313 
LVEF 46.4 ± 17 37.1 ± 13.5 43 ± 10 0.190 
ACE inhibitor 10 (52.6) 10 (47.6) 20 (50) 1.000 
ARB 6 (31.6) 6 (28.6) 12 (30) 1.000 
Statin 19 (100) 19 (100) 40 (100) - 
Antiplatelet 19 (100) 19 (100) 40 (100) - 
β-blocker 14 (73.7) 15 (71.4) 29 (72.5) 1.000 
CCB 5 (26.3) 4 (20) 9 (22.5) 0.716 
Nitrate 15 (78.9) 19 (95) 34 (85) 0.182 
 
Table 1. Baseline characteristic
ACE inhibitor = angiotensin-converting enzyme inhibitor; ACS = acute coronary syndrome; ARB = angiotensin ii receptor blockers; BMI = Body 
mass index; CCB = calcium channel blockers; CKD = chronic kidney disease; CVD = cardiovascular diseases; LVEF = left ventricular ejection 
fraction; MBG = myocardial blush grade.
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Shapiro Wilk test. Statistical analysis used for categorical variables was 
the Chi-Square test. While continuous variables were analyzed using 
the T-Test test. The confidence interval was 95%. A p-value < 0.05 was 
considered statistically significant.
3. Results
3.1. Baseline characteristic
 In the beginning, we had successfully identified 149 patients 
who have CTO proved to be the primary lesions. A total of 42 patients 
underwent percutaneous coronary intervention in CTO lesions. Howev-
er, two of them were excluded because of medication non-compliance. 
Finally, 40 patients underwent CTO recanalization included in the 
statistical analysis. The baseline characteristics of the patients between 
both groups were not significantly different (Table 1). The patient's age 
was 57 ± eight years. Most of them were male (90%). About 56% of 
patients suffered from hypertension, 40% had diabetes mellitus, 20% 
had dyslipidemia, 55% were smokers, and 20% had the familial history 
for coronary artery disease. All patients received optimal medical 
treatment for stable angina pectoris, including antiplatelet, statin, and 
one or more anti-angina.
 On angiographic analysis and procedural aspects (table 2), 7 
(18%) patients had one vessel disease, 8 (20%) had a two-vessels 
disease, 24 (60%) had three vessels disease, and 1 (3%) had left main 
disease. The chronic total occlusion percutaneous coronary intervention 
(PCI CTO) procedures were conducted for the left anterior descending 
artery, the left circumflex artery, the right coronary artery in 45%, 
12,5%, and 10% patients, respectively. The wire crossing time < 30 
minutes was achieved in 85% of patients. About 80% of patients 
received drug-eluting stent (DES) implantation, and 20% received 
bare-metal stent (BMS). The PCI CTO procedures needed <200 mL 
contrast in 32 patients. The patients' angiographic and procedural 
aspects were not significantly different, except for the dose area product 
(DAP).
3.2. Outcomes
 The follow-up period was ranging from 2 to 24 months 
following the CTO recanalization procedure. The SAQ includes physical 
limitation, angina frequency, and quality of life. The SAQ for physical 
limitation between the two groups was not significantly different 
(83.86 ± 16.11 vs. 77.92 ± 3.44; p = 0.247). The SAQ on angina 
frequency (85.27 ± 17.44 vs. 74.76 ± 22.05; p = 0.105) and SAQ for 
quality of life (73.24 ± 3.41 vs. 72.82 ± 3.56; p = 0.932) also revealed 
the similar results. Our results also revealed that good myocardial blush 
was not correlated with the reduction of antianginal drug regimens (10 
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 Table 2. Angiographic characteristics and procedural aspects 
BMS = bare metal stent; CTO = chronic total occlusion; DAP = dose area product; DES = drug eluting stent; MBG = myocardial blush grade; 
SYNTAX = synergy between percutaneous coronary intervention with taxus and cardiac surgery
Variable Good myocardial blush (MBG 2-3) 
(n = 19) 
Poor myocardial blush (MBG 0-1) 
(n = 21) 
Total
n = 40 
 
p-Value 
Number of significant lesions    0.384 
1 vessel disease 4 (21.1) 3 (14.3) 7 (18)  
2 vessels disease 5 (26.3) 3 (14.3) 8 (20)  
3 vessels disease 9 (47.4) 15 (71.4) 24 (60)  
Left main disease 1 (5.3) 0 (0.0) 1 (2.5)  
SYNTAX score    0.911 
Skor < 22 6 (31.6) 6 (28.6) 12 (30)  
Skor 22 – 32 7 (36.8) 7 (33.3) 14 (35)  
Skor >33 6 (31.6) 8 (38.1) 14 (35)  
CTO location    0,175 
Left main artery 1 (5.3) 0 (0.0) 1 (2.5)  
Left anterior descending artery 11 (57.9) 7 (33.3) 18 (45)  
Left circumflex artery 2 (10.5) 3 (14.3) 5 (12.5)  
Right coronary artery 0 (0.0) 4 (19.0) 4 (10)  
Multivessel CTO 5 (26.3) 7 (33.3) 12 (30)  
Bridging collateral 3 (15.8) 3 (14.3) 6 (15) 0,619 
Contralateral collateral  9 (47.4) 11 (52.4) 18 (45) 0,500 
Wire crossing time    0.398 
<30 minutes 15 (78.9) 19 (90.5) 34 (85)  
>30 minutes 4 (21.1) 2 (9.5) 6 (15)  
Contrast    0.241 
<200 mL 17 (89.5) 15 (71.4) 32 (80)  
>200 mL 2 (10.5) 6 (28.6) 8 (20)  
DAP (Cgy.cm2)    0,042 
<10.000 4 (21.1) 0 (0.0) 4 (10)  
>10.000 15 (78.9) 21 (100) 36 (90)  
Stent    0.654 
BMS 3 (15.8) 5 (23.8) 8 (20)  
DES sirolimus 8 (42.1) 6 (28.6) 14 (35)  
DES everolimus 6 (31.6) 9 (42.9) 15 (38)  
DES paclitaxel 2 (10.5) 1 (4.8) 3 (8)  
Complete revascularization 8 (42.1) 8 (38.1) 16 (40) 1.000 
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(52.6) vs. 8 (40); p = 0.639).
4. Discussion
 In patients with severe coronary artery disease, CTO and 
non-CTO patients' signs and symptoms cannot be distinguished. Several 
parameters were correlated with the clinical presentation of CTO, 
including the number of the coronary arteries involved, the existence of 
other concomitant coronary lesions, the presence of collateral blood 
flow, myocardial viability, and the degree of myocardial ischemia.1,5 
Lesson learned from the Flow Cardia's approach to chronic total 
occlusion recanalization (FACTOR) trial suggests that two-thirds of the 
patients referred for the trial had angina, which significantly impaired 
their quality of life.14 However, all patients included in our study 
suffered from angina. A study by Safley et al. revealed that dyspnea is 
the most common anginal equivalent symptom among CTO patients. 
That study also showed similar alleviation in both dyspnea and angina 
following PCI in CTO and non-CTO group.4
 The Synergy between Percutaneous Coronary Intervention 
with Taxus and Cardiac Surgery (SYNTAX) trial showed that CABG has 
lower major adverse cardiac and cerebrovascular events (MACCE) than 
PCI for three vessels disease and left main disease during three years 
follow up period.15 The final decision on PCI or CABG remains individ-
ual and depends on the operator and the patient. The main advantages 
of CTO PCI are improved symptoms, improved left ventricular function, 
the reduction of the need for late CABG.14,16 The revascularization 
strategy in multivessel disease with concomitant CTO might be 
challenging. In multivessel disease as the first revascularization step, 
PCI CTO might be a rational approach. In case of failure, a complete 
CABG multivessel disease revascularization might be an acceptable 
strategy.17 
 Total Occlusion Angioplasty Study–Società Italiana di 
Cardiologia Invasiva (TOAST-GISE) study revealed that the successful 
CTO PCI was related to the reduction of the one-year incidence of 
cardiovascular mortality or myocardial infarction (MI), the reduction of 
the need for CABG, and the improvement of angina freedom in most 
patients.18 CTO PCI should be conducted electively and not ad hoc. 
Separating diagnostic coronary angiography and CTO PCI allows for a 
detailed discussion with the patient about the indication, targets, risk, 
and alternatives to PCI, including optimal medical treatment or CABG. 
The risk that more specific to CTO PCI warrant discussion. These 
include the risk of donor vessel injury, perforation, tamponade, and 
radiation exposure. 
 Myocardial blush is an angiographic parameter that 
represents the adequacy of myocardial reperfusion. The previous study 
from Gai et al. revealed that higher post PCI MBG was associated with 
the improvement of total blush and ejection fraction (EF).19 At first, we 
assumed that the better myocardial blush is associated with better 
improvement of angina symptoms. However, our study failed to prove 
that hypothesis. In our study, we found that myocardial blush was not 
correlated with the improvement of angina symptoms. The SAQ for 
physical limitation, angina frequency, and quality of life were not 
significantly different between both groups. Our study also revealed 
that myocardial blush was not correlated with and the reduction of 
antianginal drug regimens. CTO recanalization restores coronary blood 
flow to the myocardium. If the CTO recanalization is accompanied by 
optimal medical treatment, the myocardial perfusion will gradually 
improve even though the MBG after the CTO PCI procedure is not good 
enough. The reduction in antianginal drug regimens between both 
groups had no significant difference. The ischemic burden of incom-
plete revascularization was the reason for nitrate administration as an 
antianginal in our study. The existing data showed that 57.5% of the 
total study participants were still incomplete revascularization. They 
were patients with multivessel lesions and required subsequent PCI 
procedures.
 As far as we are concerned, our study was the only study to 
investigate the impact of post-CTO recanalization MBG on the clinical 
outcomes of CCS patients, including the improvement of angina 
symptoms and the reduction of antianginal drug regimens. By using the 
QuBE, we could limit intra- and inter-observer variability in evaluating 
the myocardial blush. Several limitations were found in our study. First, 
this study was a retrospective study. Second, unequal follow-up period 
among the participants. It could be a significant potential for bias. 
Third, we included patients with incomplete revascularization. The 
residual angina symptoms could be the effect of the incomplete revascu-
larization. Fourth, we conducted a study with a small number of partici-
pants. However, our sample number was higher than the study by Gai 
et al.19 Last, the baseline SAQ among the participants was not assessed. 
A study with a better design and larger participants was needed to 
obtain good quality evidence.
5. Discussion
 Our study provided a preliminary overview of myocardial 
blush following the CTO PCI procedure. Myocardial blush post-CTO 
recanalization was not associated with the improvement of angina 
symptoms and the reduction of antianginal drug regimens among 
patients with CCS.
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Table 3. Outcome
SAQ = Seattle Angina Questionnaire; MBG = myocardial blush grade
Variable Good myocardial blush (MBG 2-3) 
(n = 19) 
Poor myocardial blush (MBG 0-1) 
(n = 21) 
p-Value 
SAQ - physical limitation 83.86 ± 16.11 77.92 ± 3.44 0.247 
SAQ - angina frequency 85.27 ± 17.44 74.76 ± 22.05 0.105 
SAQ - quality of life 73.24 ± 3.41 72.82 ± 3.56 0.932 
Reduction of antianginal drug 
regimens 
10 (52.6) 8 (40) 0.639 
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